Obrindatamab(TD-HV612046) is a research-grade recombinant antibody targetingCD276. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Protein A/G purified from cell culture supernatant.
Accession
Q5ZPR3 & P07766
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.
Caption
SDS-PAGE for Research Grade Obrindatamab | Detects CD276 in indirect ELISAs. ### Detects CD3E in indirect ELISAs. ### Detects CD276 in indirect ELISA. ### Detects Recombinant Human CD276 Protein, C-His (Cat No.:HV612011) in indirect ELISA. | Western blot analysis was performed using anti-CD276 monoclonal antibody at 1ug/mL on various samples.Lane 1:recombinant human CD276 (Catalog No:TD-HV612011)Lane 2:negative control
Note
For research use only. Not suitable for clinical or therapeutic use.